In vitro test systems for glucocorticoid-induced skin atrophy

Topical glucocorticoids (GCs) are anti-inflammatory effective but limited by their side effects, in particular by the induction of skin atrophy. Thus, determining the atrophogenicity of compounds is important. This study aimed to establish according invitro models. A combination of different cellular assays with markers related to collagen metabolism and epidermal thickness was investigated using standard GCs. A GC-dependent regulation of MMP expression in keratinocytes, collagen expression in 3T3 cells, as well as epidermal thickness, collagen and MMP synthesis in a full-thickness skin model was found. Demonstrating dose-dependency and correlation with GC atrophogenicity qualifyed them as candidates. The predictability of these models for invivo was finally confirmed by showing less atrophogenic effects of a novel selective GC receptor agonist (SEGRA) in comparison to clobetasol invitro subsequently comfirmed in the rat skin atrophy model. In summary, a combination of 3 invitro models is recommended to determine atrophogenicity of GC receptor ligands.

Autorentext

Stefanie Schoepe graduated in biology at the Free University of Berlin in Germany. She finished her biology studies with a diploma thesis about "Regulation of transcription of liverspecific genes by glucocorticoids". In 2009, she earned her PhD in molecular biology at the Bayer Schering Pharma AG and at the Humboldt University of Berlin.